

decrease in sucrose preference. Moreover, selective NR2B antagonist did not produce rewarding effect. These findings suggest that DAPK1 interaction with NMDA receptor NR2B subunit acts as a critical component in the rapid antidepressant actions.

Inflammation can impact the glutamatergic system enhancing excitotoxicity and decreasing neuroplasticity. Using altered peptide ligand (APL) of myelin basic protein (MBP) to immunize rats, we found that myelin-derived altered peptides produced a prolonged antidepressant-like effect by reducing the immobility in the FST and preventing CUS-induced anhedonia. The behavioral outcome was accompanied by increased c-fos expression and restoration of p11 and BDNF levels in the mPFC and dentate gyrus (DG). Moreover, intra-mPFC infusion of lentiviral vectors containing short-hairpin RNA targeting p11 blunted the antidepressant-like effects. Our findings introduce a novel immune-based therapy for treatment of depression.

NMDA receptor trafficking and function are regulated by the receptor tyrosine kinase EphB2 through dynamic interacting NMDA receptors and Src-mediated tyrosine phosphorylation. We observed decrease in EphB2 level in the mPFC of mice that were susceptible to chronic social defeat stress. Activation of EphB2 receptors in the mPFC produced stress-resistant and antidepressant-like behavioral effects in susceptible mice, while EphB2 receptor knockdown increased the susceptibility to stress and induced depressive-like behaviors in a subthreshold chronic social defeat stress paradigm. These behavioral effects were associated with changes in the phosphorylation of cofilin and expression of some synaptic proteins and stress-induced spine remodeling in the mPFC. These results indicate that EphB2 is a critical regulator of stress vulnerability and might be a potential target for the treatment of depression.

Speaker 3: Maura Furey, USA

Title: Antidepressant Effects of Antimuscarinic

Action: Clinical Efficacy and Biomarkers of Response

Abstract

Background: Conventional antidepressant therapy has remained virtually unchanged for the past 50 years. The discovery of the rapid and potent antidepressant effects of the NMDA receptor antagonist ketamine has kindled interest in pursuing new and novel mechanisms for the treatment of depression. The cholinergic neurotransmitter system is implicated in affective illness, whereby a cholinergic agonist rapidly produces depressive symptoms in currently manic bipolar patients and worsens depressive symptoms in unipolar patients. Here studies evaluating the antidepressant effects of the anticholinergic, scopolamine, and potential biomarkers of response will be discussed.

Methods: Currently unmedicated unipolar and bipolar patients participated in double-blind, placebo-controlled, crossover infusion studies using scopolamine (4mg/kg). Prior to each infusion patients completed the Profile of Mood State (POMS) and Visual Analog Scales (VAS) self-rating scales, and were assessed clinically using the Montgomery-Asberg Depression Rating Scale (MADRS). Following a single-blind placebo lead-in session, patients participated in a functional magnetic resonance imaging (fMRI) study while they performed a face-identity and face-emotion working memory task. Clinical efficacy was assessed by measuring change in MADRS over sessions. Biomarker analyses included: 1) baseline self-ratings were used in a discriminant function analysis to identify linear combinations of individual items that predict clinical response, and 2) whole brain task specific blood oxygen level-dependent (BOLD) signal at baseline was correlated with the magnitude of treatment response to scopolamine.

Results: Clinically, patients showed a rapid and robust antidepressant response following the first administration of scopolamine that exceeded the placebo response. The discriminant analysis based on baseline self-ratings separated responders from non-responders in both the unipolar and bipolar diagnostic subgroups. Baseline BOLD response in the bilateral middle occipital cortex, selectively during the emotion working memory task, correlated with the magnitude of treatment response.

Conclusion: These results indicate that antimuscarinic action by scopolamine produces rapid antidepressant effects, and that both clinical ratings and BOLD signal measured prior to treatment may predict clinical outcome. These findings implicate cholinergic and visual processing dysfunction in the pathophysiology of MDD, and suggest that both patient self-ratings and neural activity in the visual cortex may provide useful biomarkers for the identification of patients who will respond favorably to scopolamine.

References

- Furey, M.L., and Drevets, W.C. The antimuscarinic drug scopolamine offers promise as a potent antidepressant agent: A randomized, placebo-controlled clinical trial. *Archives of General Psychiatry*, 63: 1121–1129, 2006.
- Drevets, W.C., Furey, M.L. Antidepressant effects of scopolamine: a replication study. *Biological Psychiatry*, 67:432–8, 2010.
- Furey, M.L., Nugent, A.C., Speer, A., Luckenbaugh, D.A., Hoffman, E.M., Frankel, E., Drevets, W.C., Zarate C. Jr. Baseline mood-state measures as predictors of antidepressant response to scopolamine. *Psychiatric Research*, 196(1); 62–7, 2012.
- Furey, M.L., Drevets, W.C., Hoffman, E.M., Frankel, E., Speer, A.M., Zarate, C.A. Jr. Pre-treatment neural activity in visual cortex during emotional processing predicts treatment response to scopolamine in major depressive disorder. *JAMA Psychiatry*, 70(3); 1156–63, 2013.

Speaker 4: Shigeyuki Chaki, Japan

Title: Synaptic and neural mechanisms of agents with rapid acting antidepressant effects: Evidences for mGlu2/3 antagonists and ketamine

Abstract

Ketamine has been demonstrated to exert rapid and sustained antidepressant effects for patients with depression including treatment-resistant depression (TRD). However, a number of adverse effects preclude routine use of ketamine, thus, alternatives to ketamine are needed. Metabotropic glutamate (mGlu) 2/3 receptor antagonists have been demonstrated antidepressant effects in animal models, and some of the mechanisms underlying antidepressant effects are shared by ketamine, which raise the possibility that mGlu2/3 receptor antagonists could be an alternative to ketamine. Therefore, synaptic and neural mechanisms of mGlu2/3 receptor antagonists were investigated and compared with those of ketamine.

Systemic administration of mGlu2/3 receptor antagonists and ketamine exhibited rapid and sustained antidepressant effects in animal models, including those refractory to current medications. Antidepressant effects of mGlu2/3 receptor antagonists and ketamine were attenuated by NBQX (an AMPA receptor antagonist), K252a (a TrkB inhibitor) and rapamycin (an mTOR signaling inhibitor), suggesting that mGlu2/3 receptor antagonists and ketamine share synaptic mechanisms that both compounds may increase synaptic formation, which is underpinned by the reports that both compounds increase synaptic protein synthesis. Interestingly, local injection of LY341495 or ketamine into the mPFC exerted antidepressant effects in the

forced swimming test, and antidepressant effects were attenuated by local injection of NBQX into the mPFC, indicating that both an mGlu2/3 receptor antagonist and ketamine exert the effects through AMPA receptor stimulation in the mPFC. In addition, we found that depletion of serotonin blocked antidepressant effects induced by local injection of LY341495 or ketamine into the mPFC. We also found that both compounds increased the c-Fos expression in the serotonin neurons in the dorsal raphe nucleus (DRN), which was blocked by local injection of NBQX into the mPFC, suggesting that both compounds may activate subsets of serotonin neurons in the DRN regulated by AMPA receptor stimulation in the mPFC.

These studies revealed that mGlu2/3 receptor antagonists exhibited similar antidepressant profiles with ketamine in animal models in that they exerted rapid and sustained effects and were effective in animal models refractory to current medications. Moreover, mGlu2/3 receptor antagonists may share mechanisms underlying antidepressant effects with ketamine at both synaptic and neural levels. Therefore, mGlu2/3 receptor antagonists may be useful as an alternative approach to treating patients with TRD. Other agents including GLYX-13 and GluN2B antagonists which could be alternatives to ketamine will also be briefly discussed.

CP02: Anxiety

Title: Clinical perspective of Anxiety Disorders in Korea

Speaker 1: Dan Stein, South Africa

Speaker 2: Kang-Seob Oh, Republic of Korea

Abstract

Since 21st century, anxiety disorders (Generalized Anxiety disorder, Panic Disorder, Social Anxiety disorder) are no more ignorant in Korea.

Many studies including epidemiologic, clinical characteristic, and treatment studies of anxiety disorders were published in Korea.

In this session, the speaker will present about prevalence rate of anxiety disorders, clinical characteristics of anxiety disorders, and treatment results studies of anxiety disorders in Korea.

The speaker will also introduce some treatment guidelines of anxiety disorders in Korea.

14.45 – 16.30

S15: Cognitive Dysfunction in Depression: Enabling discovery and Treatment development

Chair: Barbara Sahakian, UK

Co-Chair: Si Tianmei, China

Speaker 1: Barbara Sahakian, UK

Title: Cognitive dysfunction in depression: the need for discovery, development and translation in this Domain

Abstract

Depression is a common, distressing and debilitating disorder, which is frequently chronic and relapsing. Depression

is associated with problems in cold and hot cognition (Roiser et al, 2012; Roiser & Sahakian, 2013). These problems include impairments in sustained attention, forms of memory, planning and problem solving, decision-making, as well as negative attentional bias and over-sensitivity to negative feedback (Rock et al, 2013). Therefore, it is perhaps not surprising that workplace functionality is affected by depression, with both lost earnings due to absenteeism and lower productivity on return to work or presenteeism (Beddington et al, 2008). How can we improve the cognitive outcome for patients? Early detection of depression and early effective treatment should prevent or reduce the impact on cognition (Insel, Sahakian et al, 2012; Insel, Voon et al, 2013). Fast-acting medications targeting the glutamate system, especially the NMDA receptor, directly are currently in development (ketamine: Zarate et al, 2006). Recently approved drugs, such as vortioxetine, with multi-modal action have been shown to improve performance on some tests of cold cognitive function (Katona et al, 2012; McIntyre et al, 2014). It is concluded that cognition is an important target for treatment in depression (National Academies of Sciences, Engineering, and Medicine, 2015).

References

- Beddington J, Cooper CL, Field J, Goswami U, Huppert FA, Jenkins R, Jones HS, Kirkwood TB, Sahakian BJ, Thomas SM (2008) The mental wealth of nations. *Nature*, 23, 1057–1060
- Insel TR, Sahakian BJ, Voon V, Nye J, Brown VJ, Altevogt BM, Bullmore ET, Goodwin GM, Howard RJ, Kupfer DJ, Malloch G, Marston HM, Nutt DJ, Robbins TW, Stahl S, Tricklebank MD, Williams JH (2012) A plan for mental illness. *Nature*, 483, 269.
- Insel TR, Voon V, Nye JS, Brown VJ, Altevogt BM, Bullmore ET, Goodwin GM, Howard RJ, Kupfer DJ, Malloch G, Marston HM, Nutt DJ, Robbins TW, Stahl SM, Tricklebank MD, Williams JH, Sahakian BJ (2013) Innovative solutions to novel drug development in mental health. *Neurosci. Biobehav. Rev.*, 37, 2438–2444.
- Katona C, Hansen T, Olsen CK (2012) A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. *J. Clin. Psychopharmacol.*, 27, 215–223.
- McIntyre RS, Lophaven S, Olsen CK (2014) A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. *IJNP*, 17, 1557–1567.
- National Academies of Sciences, Engineering, and Medicine. 2015. *Enabling discovery, development, and translation of treatments for cognitive dysfunction in depression: Workshop summary*. Washington, DC: The National Academies Press.
- Roiser JP, Elliott R, Sahakian BJ (2012) Cognitive mechanisms of treatment in depression. *Neuropsychopharmacology Reviews*, 37, 117–136.
- Roiser JP, Sahakian BJ (2013) Hot and cold cognition in depression. *CNS Spectrums*, 18, 139–149.
- Rock PL, Roiser JP, Riedel WJ, Blackwell AD (2013) Cognitive impairment in depression: a systematic review and meta-analysis. *Psychol Med*, 1 - 12.
- Zarate CA, Jaskaran BS, Carlson MD, Brutsche NE, Ameli R, Luckenbaugh MA, Charney DA, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. *Archives of General Psychiatry*, 63, 856–864.